Executive Director, Early-Stage Development
Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Executive Director of Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.